FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting